Next-generation clinical trials are also underway for PD-1 inhibitors in combination with other immune modulators such as anti-lymphocyte activation gene 3 (LAG3) antibody for solid tumors [64], anti-killer inhibitory receptor (KIR) antibody, lirilumab, for solid tumors [65], anti-OX40 agonistic antibody, MEDI6383, for solid tumors [66], anti-4-1BB agonistic antibody, urelumab, for solid tumors and B-cell non-Hodgkin lymphoma [67], and GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) vaccine for NSCLC [68]. Here, LAG3 is linked to B-cell non-Hodgkin lymphoma.